Search results for "Liver cirrhosis."

showing 10 items of 598 documents

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection

2009

Background Genotype 1 (G1) hepatitis C virus (HCV) is associated with insulin resistance (IR) and its clearance seems to improve insulin sensitivity. We aimed to evaluate the time course of IR in response to antiviral therapy in non-diabetic, non-cirrhotic G1 HCV patients and to assess the effect of metabolic factors on sustained virological response (SVR). Methods A total of 83 consecutive treatment-naive G1 chronic hepatitis C (CHC) patients were evaluated by anthropometric and metabolic measurements, including IR using the homeostasis model assessment (HOMA). Patients were considered to have IR if HOMA was >2.7. All cases had a liver biopsy scored for staging, grading and steatosis. A…

Liver CirrhosisMaleTime FactorsCirrhosisGenotypemedicine.medical_treatmentHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsBody Mass IndexSex FactorsInsulin resistanceDiabetes mellitusGenotypemedicineHumansPharmacology (medical)PharmacologySettore MED/12 - Gastroenterologiabusiness.industryInsulinHepatitis C ChronicMiddle Agedmedicine.diseaseANTIVIRAL THERAPYFatty LiverLogistic ModelsTreatment OutcomeInfectious DiseasesTime courseImmunologyHCVFemaleViral diseaseWaist CircumferencebusinessINSULIN RESISTANCE
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease.

2008

Background & Aims: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. Methods: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. Results: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon α. Ten years after putative exposure, the outcome in …

Liver CirrhosisMaleTime FactorsHepacivirusHepacivirusChronic hepatitis CGastroenterologyLiver diseaseViralProspective StudiesChronicProspective cohort studyChildChildrenchronic epatitis C; long term course; childrenbiologyHazard ratioGastroenterologyHepatitis CViral LoadHepatitis CTreatment OutcomeItalyChild PreschoolHCVDisease ProgressionRNA ViralFemaleViral loadmedicine.medical_specialtyAdolescentGenotypeAlpha interferonSocio-culturaleViremiaAntiviral AgentsRisk AssessmentHEPATITISInternal medicinemedicineHumansViremiaAdolescent; Antiviral Agents; Child; Child Preschool; Disease Progression; Female; Genotype; Hepatitis C Chronic; Humans; Infant; Interferon-alpha; Italy; Liver Cirrhosis; Male; Proportional Hazards Models; Prospective Studies; RNA Viral; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; Viral Load; Viremia; Hepacivirus; GastroenterologyPreschoolProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryLong-term courseInfantInterferon-alphaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseImmunologyRNAbusinessGastroenterology
researchProduct

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.

2015

Background and rational. Telaprevir-based therapy (TBT) has been extensively evaluated in clinical trials. So we designed a study to compare the efficacy and safety of TBT between patients with moderate fibrosis and those suffering from advanced fibrosis in clinical practice. A multicenter observational and ambispective study was conducted. It included 582 patients with chronic hepatitis C genotype 1, 214 with fibrosis F2, and 368 with F3/F4 (F3: 148; F4: 220). Results. The mean patient age was 55 years, 67% male. Type of prior response was 22% naive, 57% relapsers, and 21% partial/null responders, 69% had high viral load (> 800,000 IU/mL). HCV genotypes were 1a (19%), 1b (69%), and 1 (12%)…

Liver CirrhosisMaleTime FactorsSpecialties of internal medicineHepacivirusGastroenterologySeverity of Illness IndexTelaprevirFibrosisRisk FactorsGenotypeGeneral MedicineMiddle AgedViral LoadTreatment OutcomeRC581-951Hepatitis C genotype 1RNA ViralDrug Therapy CombinationFemaleTelaprevir triple therapyModerate fibrosisViral loadOligopeptidesmedicine.drugAdultmedicine.medical_specialtyGenotypeAntiviral AgentsSafety and efficacyYoung AdultInternal medicinemedicineHumansAdverse effectAgedHepatologybusiness.industryInterleukinsHepatitis C Chronicmedicine.diseaseSurgeryDiscontinuationClinical trialSpainObservational studyInterferonsbusinessBiomarkersAnnals of hepatology
researchProduct

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

2011

Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum lev…

Liver CirrhosisMaleTime Factorsmedicine.medical_treatmentBiopsyMenopause PrematuremenopauseHepacivirusmedicine.disease_causeGastroenterologySeverity of Illness IndexRisk FactorsOdds RatioProspective StudiesTreatment FailureProspective cohort studymedicine.diagnostic_testGastroenterologyAge FactorsHormone replacement therapy (menopause)Hepatitis CMiddle AgedViral LoadImmunohistochemistryMenopauseItalyLiver biopsyRNA ViralFemaleInflammation Mediatorshcv svr menopauseViral loadAdultmedicine.medical_specialtyantiviral therapy; menopause; prognostic factors; hcv therapyGenotypeHepatitis C virusAntiviral AgentsRisk AssessmentSex FactorsInternal medicinehcvmedicineHumanshcv; ifn; menopauseHepatologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaOdds ratioHepatitis C Chronicmedicine.diseaseifnEndocrinologyLogistic ModelsbusinessBiomarkersGastroenterology
researchProduct

Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.

2013

Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (p…

Liver CirrhosisMaleTuberculosisTime Factorsmedicine.medical_treatmentHepatosplenomegalyAntitubercular AgentsSpecialties of internal medicineHepacivirusLiver transplantationVHCAntiviral AgentsLymphohistiocytosis HemophagocyticTelaprevirTelaprevirchemistry.chemical_compoundFatal OutcomePegylated interferonRisk FactorsmedicineHumansTuberculosisHepatologyHaemophagocytic syndromebusiness.industryRibavirinGeneral MedicineMycobacterium tuberculosisMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationTransplantationchemistryRC581-951ImmunologyDrug Therapy CombinationVirus Activationmedicine.symptombusinessOligopeptidesImmunosuppressive Agentsmedicine.drugRare diseaseAnnals of hepatology
researchProduct

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

2015

EA Pôle MERS Hors CT hors EJ; International audience; Background & Aims: To compare the management of chronic hepatitis B (CHB) and its evolution over time in currently followed HIV-positive and HIV-negative patients. Methods: A total of 709 consecutive patients with past or present positive HBs antigenemia seen in October 2012 in 19 French participating centres were included. The data were retrospectively collected from the first visit onwards through standardized questionnaires. Results: Chronic hepatitis B was less often assessed in the 299 HIV-positive patients, who were older, more likely to be male, excessive alcohol drinkers and HBe antigen-, HCV- and HDV-positive. They were also fol…

Liver CirrhosisMale[SDE] Environmental SciencesCirrhosis[SDV]Life Sciences [q-bio]HIV InfectionsComorbidityCohort Studies0302 clinical medicineReference ValuesHIV SeropositivityHBV[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHIV SeronegativityLiver NeoplasmsLamivudinevirus diseasesEntecavirhepatocellular carcinomaMiddle Aged3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeLamivudineHepatocellular carcinoma[SDE]Environmental SciencesDisease ProgressionFemale030211 gastroenterology & hepatologyFranceCohort studymedicine.drugAdultmedicine.medical_specialtyGuanineAntiviral AgentsRisk AssessmentStatistics Nonparametric03 medical and health sciencesHepatitis B ChronicHIV SeronegativityInternal medicinemedicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySurvival analysisRetrospective StudiesHepatitis B Surface AntigensHepatologybusiness.industrycirrhosisHIVmedicine.diseaseSurvival AnalysisComorbiditytenofovirLogistic ModelsMultivariate AnalysisImmunologybusinessentecavir
researchProduct

Prevention of Hepatocellular Carcinoma

2005

The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for HCC are still insufficient; thus, accurate risk prediction of developing cancer in individual patients remains an elusive goal. Future directions in chemprevention of HCC will be on the development of molecular risk models and of new chemopreventive agents. The design of targeted molecular therapies may need to be tailored to the specific molecular phenotype of a specific HCC. Studies examining multiple genes and proteins (genomics and proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. In the setting of primary prevention, the epidemiologic …

Liver CirrhosisMaleadefovirOncologymedicine.medical_specialtyCarcinoma HepatocellularAntiviral AgentsRisk AssessmentSensitivity and SpecificityGastroenterologyHepatitis B Chronicpolyprenoic acidretinoidInternal medicinemedicineHumansMass Screeningantineoplastic agentReliability (statistics)Randomized Controlled Trials as TopicHepatologybusiness.industryLiver NeoplasmsCancerinterferonHepatitis C ChronicPrognosismedicine.diseaseSurvival AnalysisPrimary Preventionhepatitis C vaccineHepatocellular carcinomaFemaleInterferonslamivudinebusinesshepatitis B vaccineClinics in Liver Disease
researchProduct

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrho…

2018

Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real-life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12). Results: Eighty-seven patients were enrolled (75.9% males, mean age 58.4 ±…

Liver CirrhosisMalehepatitis C virusPyrrolidinesCirrhosisSofosbuvirmedicine.medical_treatmentantiviral treatmentHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrencehepatitis C viruProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologialiver transplantationdirect antiviral agentsImidazolesValineHepatitis CMiddle AgedPrognosisHepatitis CItalyHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyDaclatasvirHepatitis C virusAntiviral Agentsantiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation03 medical and health sciencesInternal medicineRibavirinmedicineHumansTransplantationdirect antiviral agentbusiness.industryRibavirincirrhosismedicine.diseasechemistryCarbamatesSofosbuvirbusinessFollow-Up Studiescirrhosi
researchProduct

Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

2014

BACKGROUND AND AIMS: Variant in glucokinase regulatory protein (GCKR), associated with lipid and glucose traits, has been suggested to affect fatty liver infiltration. We aimed to assess whether GCKR rs780094 C-->T SNP influences the expression of steatosis, lobular inflammation and fibrosis in NAFLD patients, after correction for PNPLA3 genotype. METHODS: In 366 consecutive NAFLD patients (197 from Sicily, and 169 from center/northern Italy), we assessed anthropometric, biochemical and metabolic features; liver biopsy was scored according to Kleiner. PNPLA3 rs738409 C>G and GCKR rs780094 C>T single nucleotide polymorphisms were also assessed. RESULTS: At multivariate logistic regression an…

Liver CirrhosisMalelcsh:MedicineNonalcoholic SteatohepatitisGene FrequencyFibrosisMedicineProspective Studieslcsh:ScienceSicilyliver fibrosisSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testGlucokinase regulatory proteinbiologyLiver DiseasesFatty liverMiddle Aged3. Good healthItalyLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyNAFLD GCKRGenotypeGENETICSgene polymorphismSingle-nucleotide polymorphismGastroenterology and HepatologyGLUCKINASESettore MED/08 - Anatomia PatologicaPolymorphism Single NucleotideNAFLDInternal medicineHumansGenetic Predisposition to DiseaseBiologySettore MED/42 - IGIENE GENERALE E APPLICATATriglyceridesPNPLA3Adaptor Proteins Signal TransducingEvolutionary BiologyPopulation Biologybusiness.industrylcsh:RSettore MED/09 - MEDICINA INTERNAComputational BiologyMembrane Proteinsnon-alcoholic fatty liver diseaseLipasePolymorphysmmedicine.diseaseLogistic ModelsEndocrinologyMetabolic DisordersMultivariate AnalysisGenetic Polymorphismbiology.proteinlcsh:QGlucokinase regulatory proteinGene polymorphismSteatosisSteatohepatitisbusinessPopulation GeneticsSteatohepatiti
researchProduct